A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

Authors

Raffael Nachbagauer

Published

December 7, 2020

Abstract

Supporters

Support the authors with ResearchCoin

Journal

Nature Medicine

Topics

DOI

10.1038/s41591-020-1118-7

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

Authors

Raffael Nachbagauer

Published

December 7, 2020

Abstract

Supporters

Support the authors with ResearchCoin

Journal

Nature Medicine

Topics

DOI

10.1038/s41591-020-1118-7

Paper

Paper

Paper

Paper

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

Abstract

Supporters

Journal

Topics

DOI

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

Abstract

Supporters

Journal

Topics

DOI